Who are Antocin Ii's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Minirin, Argipressin, NPSP558.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atosiban.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Antocin Ii — Competitive Intelligence Brief

Antocin Ii (ATOSIBAN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: atosiban. Area: Other.

marketed atosiban Vasopressin V1a receptor Other Recombinant protein Live · refreshed every 30 min

Target snapshot

Antocin Ii (ATOSIBAN) — Ferring Pharmaceuticals A/S.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Antocin Ii TARGET	ATOSIBAN	Ferring Pharmaceuticals A/S	marketed	atosiban	Vasopressin V1a receptor	2000-01-01
Minirin	Minirin	Hormozgan University of Medical Sciences	marketed		Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
Argipressin	Argipressin	Kristina Svennerholm	marketed		Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
NPSP558	NPSP558	Shire	phase 3	Vasopressin V1a receptor antagonist	Vasopressin V1a receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (atosiban class)

Ferring Pharmaceuticals A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antocin Ii — Competitive Intelligence Brief. https://druglandscape.com/ci/atosiban. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab